Literature DB >> 19351228

Therapeutic options for infections due to vancomycin-resistant enterococci.

Jiun-Ling Wang1, Po-Ren Hsueh.   

Abstract

BACKGROUND: Vancomycin-resistant enterococci (VRE) are an important cause of nosocomial infection occurring in critical care or immunocompromised patients.
OBJECTIVES: To provide updated information about therapeutic options for VRE infection.
METHODS: MEDLINE, EMBASE, and the Cochrane Library were searched to identify in vitro susceptibility data of VRE isolates, randomized and non-randomized controlled trials, case series, and cohort studies of VRE therapy published before 31 July 2008. RESULTS/
CONCLUSION: The updated in vitro susceptibility data for VRE show high resistance to ampicillin and aminoglycosides. Quinupristin-dalfopristin is limited by its lack of activity against vancomycin-resistant Enterococcus faealis and its musculoskeletal side effects. Emerging linezolid resistance has been reported to cause hospital spread and may be related to prolonged linezolid use. Quinupristin-dalfopristin resistance is usually linked to agricultural use of streptogramin. Nitrofurantoin and fosfomycin are alternatives in uncomplicated VRE urinary tract infection. Daptomycin and tigecycline have shown excellent potential for treating VRE infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19351228     DOI: 10.1517/14656560902811811

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  14 in total

1.  Determination of comparative minimum inhibitory concentration (MIC) of bacteriocins produced by enterococci for selected isolates of multi-antibiotic resistant Enterococcus spp.

Authors:  Maryam Hassan; Yousef Javadzadeh; Farzaneh Lotfipour; Rajabali Badomchi
Journal:  Adv Pharm Bull       Date:  2011-12-15

2.  Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods.

Authors:  Ching-Lan Lu; Chia-Ying Liu; Yu-Tsung Huang; Chun-Hsing Liao; Lee-Jene Teng; John D Turnidge; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2011-06-13       Impact factor: 5.191

Review 3.  The immune response and antibacterial therapy.

Authors:  Olachi Anuforom; Graham R Wallace; Laura V Piddock
Journal:  Med Microbiol Immunol       Date:  2014-09-05       Impact factor: 3.402

4.  Oral Fosfomycin Treatment for Enterococcal Urinary Tract Infections in a Dynamic In Vitro Model.

Authors:  Iain J Abbott; Elke van Gorp; Aart van der Meijden; Rixt A Wijma; Joseph Meletiadis; Jason A Roberts; Johan W Mouton; Anton Y Peleg
Journal:  Antimicrob Agents Chemother       Date:  2020-05-21       Impact factor: 5.191

5.  Benzimidazole-based antibacterial agents against Francisella tularensis.

Authors:  Kunal Kumar; Divya Awasthi; Seung-Yub Lee; Jason E Cummings; Susan E Knudson; Richard A Slayden; Iwao Ojima
Journal:  Bioorg Med Chem       Date:  2013-04-03       Impact factor: 3.641

6.  Trends in susceptibility of vancomycin-resistant Enterococcus faecium to tigecycline, daptomycin, and linezolid and molecular epidemiology of the isolates: results from the Tigecycline In Vitro Surveillance in Taiwan (TIST) study, 2006 to 2010.

Authors:  Hsih-Yeh Tsai; Chun-Hsing Liao; Yen-Hsu Chen; Po-Liang Lu; Cheng-Hua Huang; Chin-Te Lu; Yin-Ching Chuang; Shih-Ming Tsao; Yao-Shen Chen; Yung-Ching Liu; Wei-Yu Chen; Tsrang-Neng Jang; Hsiu-Chen Lin; Chih-Ming Chen; Zhi-Yuan Shi; Sung-Ching Pan; Jia-Ling Yang; Hsiang-Chi Kung; Chun-Eng Liu; Yu-Jen Cheng; Jien-Wei Liu; Wu Sun; Lih-Shinn Wang; Wen-Chien Ko; Kwok-Woon Yu; Ping-Cherng Chiang; Ming-Hsun Lee; Chun-Ming Lee; Gwo-Jong Hsu; Po-Ren Hsueh
Journal:  Antimicrob Agents Chemother       Date:  2012-04-09       Impact factor: 5.191

7.  Variation in potency and spectrum of tigecycline activity against bacterial strains from U.S. medical centers since its approval for clinical use (2006 to 2012).

Authors:  Helio S Sader; David J Farrell; Robert K Flamm; Ronald N Jones
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

8.  Revisiting Nitrofurantoin for Vancomycin Resistant Enterococci.

Authors:  Suneeta Meena; Sarita Mohapatra; Seema Sood; Benu Dhawan; Bimal Ku Das; Arti Kapil
Journal:  J Clin Diagn Res       Date:  2017-06-01

9.  Effect of Vancomycin on Cytoplasmic Peptidoglycan Intermediates and van Operon mRNA Levels in VanA-Type Vancomycin-Resistant Enterococcus faecium.

Authors:  Shivani Gargvanshi; Harika Vemula; William G Gutheil
Journal:  J Bacteriol       Date:  2021-07-22       Impact factor: 3.490

Review 10.  Daptomycin versus linezolid for treatment of vancomycin-resistant enterococcal bacteremia: systematic review and meta-analysis.

Authors:  Yu-Chung Chuang; Jann-Tay Wang; Hsin-Yi Lin; Shan-Chwen Chang
Journal:  BMC Infect Dis       Date:  2014-12-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.